Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-08
2005-11-08
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S438000, C514S462000, C549S030000, C549S200000, C549S300000, C549S322000, C549S337000, C549S341000, C548S407000
Reexamination Certificate
active
06962938
ABSTRACT:
The present application describes novel spiro-cyclic β-amino acid derivatives of formula I:or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-13 membered carbocycle or heterocycle, ring C forms a 3-11 membered spiro-carbocycle or spiro-heterocycleon ring B, and the other variables are defined in the present specification, which are useful as as matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), and/or aggrecanase inhibitors.
REFERENCES:
patent: 4261990 (1981-04-01), Bowman
patent: 6489316 (2002-12-01), Sandanayaka et al.
patent: 780386 (1997-06-01), None
patent: 818442 (1998-01-01), None
patent: WO 9720824 (1997-06-01), None
Chen Xiao Tao
Duan Jingwu
Ott Gregory R.
Voss Matthew E.
Bristol-Myers Squibb Pharma Company
Desai Rita
Sun Jing G.
Vance David H.
LandOfFree
Spiro-cyclic β-amino acid derivatives as inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Spiro-cyclic β-amino acid derivatives as inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spiro-cyclic β-amino acid derivatives as inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3453347